KEYTRUDA® (Pembrolizumab)

The FDA on November 9, 2018 granted accelerated approval to KEYTRUDA® for patients with Hepatocellular Carcinoma (HCC) who have been previously treated with Sorafenib. KEYTRUDA® is a product of Merck & Co. Inc.